TORONTO and AACHEN, Germany, Feb. 5, 2026 /CNW/ - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, ...
Bayer is selling its testosterone treatment Nebido to German pharmaceutical firm Gruenenthal in a deal valued up to 500 million euros ($500.95 million), it said on Thursday. BERLIN, July 14 (Reuters) ...
Indevus Pharmaceuticals Says Testosterone Therapy Trial Meets Primary Goal LEXINGTON, Mass., June 7 -- Indevus Pharmaceuticals, Inc. today announced final results from its Phase III pharmacokinetic ...
LEXINGTON, Mass., June 4 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that based on a recent discussion with the U.S. Food and Drug Administration (FDA) regarding the ...
AACHEN, Germany, July 14, 2022 /PRNewswire/ -- Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire Nebido TM, the ...
AACHEN, Germany and TORONTO, Feb. 5, 2026 /PRNewswire/ -- Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results